BioLineRx (BLRX) Cash from Financing Activities (2013 - 2025)

BioLineRx's Cash from Financing Activities history runs 13 years deep, the most recent figure standing at -$1.3 million for Q4 2025.

• On a quarterly basis, Cash from Financing Activities fell 12.89% year-over-year to -$1.3 million in Q4 2025; TTM through Dec 2025 was $8.9 million, a 56.99% decrease from a year earlier, with the FY2025 full-year figure at $8.9 million, down 56.99% from the prior year.
• Cash from Financing Activities eased to -$1.3 million in Q4 2025 per BLRX's latest filing, from -$916000.0 in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $41.9 million in Q1 2021 and bottomed at -$1.3 million in Q4 2025.
• The 5-year median for Cash from Financing Activities is $62500.0 (2021), against an average of $6.1 million.
• Biggest YoY gain for Cash from Financing Activities was 17920.15% in 2024; the steepest drop was 1724.49% in 2024.
• Year by year, Cash from Financing Activities stood at $174000.0 in 2021, then plunged by 471.84% to -$647000.0 in 2022, then jumped by 1914.53% to $11.7 million in 2023, then sank by 109.45% to -$1.1 million in 2024, then decreased by 12.89% to -$1.3 million in 2025.
• Per Business Quant, the three latest BLRX Cash from Financing Activities figures stand at -$1.3 million (Q4 2025), -$916000.0 (Q3 2025), and $1.6 million (Q2 2025).